Previous 10 | Next 10 |
Ocugen, Inc. (OCGN) is expected to report $-0.08 for Q3 2023
2023-11-08 12:42:29 ET More on Ocugen Ocugen (OCGN) Q2 2023 Earnings Call Transcript Ocugen mucosal vaccine selected for U.S. COVID vaccine initiative Ocugen delays plans for inhaled vaccine platform Seeking Alpha’s Quant Rating on Ocugen Histo...
2023-11-08 10:38:30 ET Major earnings expected before the bell on Thursday include: AstraZeneca ( AZN ) Fiverr International ( FVRR ) Li Auto ( LI ) Novavax ( NVAX ) Petróleo Brasileiro S.A. ( PBR ) For further details see: Nota...
MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chi...
MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live...
2023-10-10 10:16:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Archer Aviation (NYSE: ACHR ) stock is on the move Tuesday following a short report against one of the electric vertical takeoff and landing (eVTOL) company’s rivals. ...
2023-10-10 09:58:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen (NASDAQ: OCGN ) stock is on the rise Tuesday after the clinical-stage biopharmaceutical company announced a new vaccine trial . According to a press release from ...
2023-10-10 08:10:35 ET More on Ocugen Ocugen (OCGN) Q2 2023 Earnings Call Transcript Ocugen delays plans for inhaled vaccine platform Ocugen GAAP EPS of -$0.10 misses by $0.03 Seeking Alpha’s Quant Rating on Ocugen Historical earnings data for ...
NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent to identify the most effective platforms and delivery routes OCU500 will be tested as both inhaled and intranasal vaccine candidates Clinical trials scheduled to ...
MALVERN, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief E...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...